Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jian-An Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Zhigao Wang, Xinjing Ma, Wei ShiJournal for ImmunoTherapy of Cancer 2024 · DOI

Abstract: NCT03134872.

Introduction

The 5-year update of the CameL phase 3 study provides critical long-term evidence for the efficacy of camrelizumab, an anti-PD-1 antibody, in combination with standard chemotherapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Historically, advanced NSCLC carried a poor prognosis; however, this study demonstrates a durable survival benefit, with nearly one-third of patients in the combination group alive at the five-year mark—a significant milestone in the treatment of this disease.

Study Design and Methodology

The CameL study was a randomized, open-label, multicenter phase 3 trial involving 412 patients across 52 sites in China. Participants with previously untreated, advanced non-squamous NSCLC without EGFR or ALK mutations were randomized to receive either:

  • Experimental Arm: Camrelizumab + Carboplatin + Pemetrexed (n=205)
  • Control Arm: Carboplatin + Pemetrexed alone (n=207)

Patients received 4–6 cycles of the combination therapy followed by maintenance. Notably, the trial allowed for crossover, permitting patients in the chemotherapy-only group to receive camrelizumab monotherapy upon disease progression. To account for the potential confounding effect of crossover on survival data, researchers utilized a Rank-Preserving Structural Failure Time (RPSFT) model to calculate adjusted Hazard Ratios (HR).

Key Results

The 5-year analysis, with a median follow-up of 65.2 months, confirms the sustained superiority of the camrelizumab combination over chemotherapy alone.

Overall Survival (OS)

The median OS was significantly longer in the combination group (27.1 months) compared to the chemotherapy group (19.8 months), representing a Hazard Ratio of 0.74. When adjusted for crossover using the RPSFT model, the HR improved to 0.62. Most importantly, the 5-year OS rate was 31.2% for the combination arm versus 19.3% for the control arm.

Overall survival (OS) in the intention-to-treat population.

Progression-Free Survival and Response Durability

The 5-year Progression-Free Survival (PFS) rate was 16.1% for the combination group, compared to just 3.0% for the chemotherapy group. Furthermore, the duration of response (DoR) highlights the persistence of the treatment effect: the 5-year DoR rate was 21.3% in the combination group, whereas no patients in the chemotherapy-only group maintained a response for five years.

Duration of response (DoR) in the intention-to-treat population.

Clinical Insights

The "Survival Tail" and Long-term Responders

The Kaplan-Meier curves for OS exhibit a distinct "tail," where the survival probability flattens after approximately three years. This indicates that a subset of patients achieves long-term, stable disease control. A particularly striking finding was observed in the "2-year completers"—the 33 patients who finished the maximum permitted 2 years of camrelizumab. In this cohort, the 5-year OS rate reached an extraordinary 84.3%, suggesting that two years of therapy may be sufficient to "reset" the immune system in responders.

Impact of Crossover

Despite a high effective crossover rate (52.7% of the chemotherapy group eventually received immunotherapy), the first-line combination group maintained a statistically significant survival advantage. This underscores the importance of utilizing immune checkpoint inhibitors in the first-line setting rather than reserving them for second-line treatment.

Safety and Tolerability

The long-term safety profile remained manageable, with no new or late-onset safety signals identified. Reactive cutaneous capillary endothelial proliferation (RCCEP), a skin-related side effect characteristic of camrelizumab, was the most common immune-mediated event but was primarily Grade 1-2 and self-limiting.

Conclusion

The CameL study establishes camrelizumab plus chemotherapy as a potent first-line option for advanced non-squamous NSCLC, offering a substantial chance for 5-year survival. While the study was conducted in a Chinese population, the results contribute significantly to the global understanding of long-term ICI efficacy. Future research will focus on identifying biomarkers to better predict long-term survivors and exploring optimal treatment durations for patients who do not achieve a complete response within the initial two years.

Summary updated

Abstract

NCT03134872.
BibTeX
@article{zhou2024camrelizumab,
  author = {Caicun Zhou and Gongyan Chen and Yunchao Huang and Jianying Zhou and Lizhu Lin and Jifeng Feng and Zhehai Wang and Yongqian Shu and Jianhua Shi and Yi Hu and Qiming Wang and Ying Cheng and Fengying Wu and Jianhua Chen and Xiaoyan Lin and Yongsheng Wang and Jian-An Huang and Jiuwei Cui and Lejie Cao and Yunpeng Liu and Yiping Zhang and Yueyin Pan and Jun Zhao and Liping Wang and Jianhua Chang and Qun Chen and Xiubao Ren and Wei Zhang and Yun Fan and Zhiyong He and Jian Fang and Kangsheng Gu and Xiaorong Dong and Faguang Jin and Hongjun Gao and Guangyu An and Cuimin Ding and Xiaodong Jiang and Jianping Xiong and Xiangdong Zhou and Sheng Hu and Ping Lu and Anwen Liu and Shuliang Guo and Jianjin Huang and Chengchu Zhu and Jian Zhao and Beili Gao and Yinglan Chen and Chengping Hu and Jian Zhang and Hongmei Zhang and Hui Zhao and Zhigao Wang and Xinjing Ma and Wei Shi},
  title = {{Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009240},
}
Figure